Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 975-982

  Bu, He Qi ^a   Liu, Dian Lei ^b   Wei, Wei Tian ^c   Chen, Liang ^d   Huang, Hai ^b   Li, Ye ^b   Cui, Jun Hui ^a  

^a TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b Hangzhou Hospital of Traditional Chinese Medicine   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Caspases; Oridonin; p38; p53; Pancreatic cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; ORIDONIN; PIFITHRIN ALPHA; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CASPASE 3 GENE; CASPASE 9 GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GAPDH GENE; GENE; HUMAN; HUMAN CELL; P21 GENE; P38 GENE; P53 GENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTHRACENES; APOPTOSIS; BENZOTHIAZOLES; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES, KAURANE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PLANT PREPARATIONS; PYRIDINES; RABDOSIA; RNA, MESSENGER; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892404410     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2888     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Löhr M: Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 3: 236-237, 2006.
3. Omura N and Goggins M: Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2: 310-326, 2009.
4. Tan W, Lu J, Huang M, et al: Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med 6: 27, 2011.
5. Gao FH, Hu XH, Li W, et al: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
6. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAF-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 490: 70-75, 2009.
7. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2008.
8. Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through AKT and MAPKS signaling pathways in human osteosarcoma cells. Cancer Biol Ther 6: 261-268, 2007.
9. Li D, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induced A431 cell apoptosis partially through blockage of the RAS/RAF/ERK signal pathway. J Pharmacol Sci 103: 56-66, 2007.
10. Hu HZ, Yang YB, Xu XD, et al: Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28: 1819-1826, 2007.
11. Liu YQ, Mu ZQ, You S, et al: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 29: 1873-1879, 2006.
12. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
13. Ikezoe T, Chen SS, Tong XJ, et al: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
14. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
15. Perfettini JL, Castedo M, Nardacci R, et al: Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med 201: 279-289, 2005.
16. Kuribayashi K and El-Deiry WS: Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 615: 201-221, 2008.
17. Fuster JJ, Sanz-González SM, Moll UM and Andrés V: Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 13: 192-199, 2007.
18. Burns TF, Fei P, Scata KA, et al: Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23: 5556-5571, 2003.
19. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007.
20. Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12: 4839-4854, 2007.
21. Lee JT, Lehmann BD, Terrian DM, et al: Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7: 1745-1762, 2008.
22. McCubrey JA, LaHair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789, 2006.
23. Kholodenko BN and Birtwistle MR: Four-dimensional dynamics of MAPK information processing systems. Wiley Interdiscip Rev Syst Biol Med 1: 28-44, 2009.
24. Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, et al: MAP kinases and prostate cancer. J Signal Transduct 2012: 169170, 2012.
25. Schaeffer HJ and Weber MJ: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435-2444, 1999.
26. Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res 15: 11-18, 2005.
27. Whyte J, Bergin O, Bianchi A, McNally S and Martin F: Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 11: 209, 2009.
28. Royuela M, Rodríguez-Berriguete G, Fraile B and Paniagua R: TNF-α/IL-1/NF-κB transduction pathway in human cancer prostate. Histol Histopathol 23: 1279-1290, 2008.
29. Thornton TM and Rincon M: Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 5: 44-51, 2009.
30. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
31. Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161, 2004.
32. Bulavin DV and Fornace AJ Jr: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118, 2004.
33. Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene 22: 8543-8567, 2003.